RZC Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Pre-tax Adjusted Operating Income: $761 million, or $8.89 per share after tax.

Adjusted Operating Return on Equity: 18.4% over the trailing 12 months.

Traditional Premium Growth: 2.2% overall; 10.5% growth in total premiums (excluding PRT).

Investment Performance:

Core portfolio yield: 4.96%

New money rate: 6.02%

Annualized returns for variable investment income (VII): 15% for the quarter, 11% year-to-date.

Shareholder Returns: $111 million returned, including $50 million in share repurchases and a 5.4% dividend increase.

2Strategic Updates and Business Highlights

Strong performance across all regions (Asia Pacific, EMEA, and U.S.) driven by new business and investment income.

Notable transactions included a Hong Kong flow co-insurance treaty and expansion in EMEA.

Focus on disciplined capital deployment, with nearly $500 million invested year-to-date in in-force transactions.

Continued emphasis on biometric risk management and strategic underwriting programs, with volumes expected to double.

3Forward Guidance and Outlook

Confidence in meeting or exceeding intermediate-term financial targets for 2026 and beyond.

Targeting 8%-10% EPS growth and 13%-15% return on equity.

Healthy pipeline of opportunities, with a disciplined approach to capital allocation and risk management.

4Bad News, Challenges, or Points of Concern

Traditional premium growth in the U.S. has been impacted by in-force management actions, although underlying growth remains solid.

The corporate segment reported an adjusted operating loss before tax of $35 million.

Concerns regarding potential impacts from changes in tax law affecting the Hong Kong market and the MCB business.

Increased asset leverage due to growth in asset-intensive business, which may raise scrutiny from investors.

5Notable Q&A Insights

Mortality Trends: Favorable mortality experience noted, particularly in group life and individual life, with claims in line with expectations.

Capped Cohorts: A 25% reduction in capped cohort exposure was achieved through management actions, with an ongoing goal to reduce this further.

Capital Deployment: Year-to-date deployment of $500 million is in line with expectations, with a focus on high-quality opportunities.

Earnings Mix: The company is focusing on balancing spread-based earnings with traditional underwriting, emphasizing the importance of biometric risk.

Equitable Transaction: The integration of the Equitable business is on track, with claims experience aligning with expectations. This summary encapsulates the key financial metrics, strategic initiatives, forward guidance, and notable insights from the Q&A, providing a balanced view of RZC's performance and outlook.